Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Homology Medicines, Inc.
The lawsuit seeks to recover losses for shareholders who purchased Homology between June 10, 2019 and February 18, 2022.
Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until May 24, 2022 to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
According to a filed complaint, Homology Medicines, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI102 in its present form; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887